Management of cardiovascular complications of bruton tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Management of cardiovascular complications of bruton tyrosine kinase inhibitors

Published:2021-09-08 Issue:1 Volume:196 Page:70-78
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Tang Chloe Pek Sang¹^ORCID,Lip Gregory Y.H.²³,McCormack Terry⁴,Lyon Alexander R.⁵,Hillmen Peter⁶^ORCID,Iyengar Sunil⁷^ORCID,Martinez‐Calle Nicolas⁸,Parry‐Jones Nilima⁹^ORCID,Patten Piers E.M.¹⁰,Schuh Anna¹,Walewska Renata¹¹,

Affiliation:

1. Oxford University Hospitals NHS Trust OxfordUK

2. Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart & Chest Hospital Liverpool UK

3. Department of Clinical Medicine Aalborg University Aalborg Denmark

4. Hull York Medical School HullUK

5. Royal Brompton NHS Trust LondonUK

6. Leeds Teaching Hospital NHS Trust LeedsUK

7. Royal Marsden Hospital NHS Trust SuttonUK

8. Nottingham University Hospitals NHS Trust NottinghamUK

9. Aneurin Bevan University Health Board AbergavennyUK

10. Comprehensive Cancer Centre Kings College London LondonUK

11. University Hospitals Dorset NHS Trust Poole UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17788

Reference84 articles.

1. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors

2. Cardiovascular Toxicities Associated With Ibrutinib

3. Hypertension management in cardio‐oncology;Essa H;J Hum Hypertens,2020

4. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

5. Cardiovascular adverse events of ibrutinib

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study;International Immunopharmacology;2024-01

2. Cardiovascular side effects of signaling pathway inhibitors in chronic lymphocytic leukemia therapy;Onkologie;2023-11-29

3. Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL;Frontiers in Pharmacology;2023-08-16

4. Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review;International Cancer Conference Journal;2023-06-26

5. The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives;Cancers;2023-05-03